Trevi Therapeutics Inc.
- Address
- 195 Church Street
Sponsor Overview
Specializations
Idiopathic Pulmonary Fibrosis and Chronic Cough
Trevi Therapeutics Inc. focuses its clinical research activity on idiopathic pulmonary fibrosis with a particular interest in the burden of chronic cough associated with the disease. The sponsor’s trial activity is centered on respiratory symptoms that affect daily functioning and disease experience in pulmonary fibrosis.
- Respiratory symptom management
- Cough frequency assessment
- Fibrotic lung disease
Its research in this area reflects a therapeutic emphasis on symptom relief in interstitial lung disease, especially where persistent cough is a major clinical concern.
Objective Cough Measurement and Digital Monitoring
The sponsor’s clinical work includes the use of objective digital cough monitoring to evaluate respiratory outcomes in IPF. This places emphasis on quantifying cough burden through direct measurement of 24-hour cough frequency.
- Digital respiratory endpoints
- Continuous cough monitoring
- Symptom quantification
This area highlights interest in precise assessment tools for cough-related outcomes in pulmonary research.
Nalbuphine Extended-Release in Respiratory Symptom Care
Trevi Therapeutics is investigating nalbuphine extended-release for the treatment of cough in idiopathic pulmonary fibrosis, indicating a therapeutic focus on agents aimed at reducing respiratory symptom burden. The research is directed toward antitussive therapy in a chronic fibrotic lung condition.
- Antitussive treatment
- Extended-release oral therapy
- Respiratory pharmacotherapy
This work sits within the broader field of symptom-directed pulmonary treatment, with attention to persistent cough in fibrotic lung disease.
Multinational Respiratory Clinical Research
The sponsor’s trial activity spans multiple countries and collaborating research sites, supporting clinical investigation in respiratory medicine across an international setting. The active research footprint is concentrated on a single pulmonary indication with cross-site participation.
- International site network
- Multicountry clinical research
- Pulmonary trial operations
Its clinical interests remain centered on cough in idiopathic pulmonary fibrosis within a coordinated respiratory research program.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Nalbuphine Hydrochloride Extended-Release Tablets for Cough Management in Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Study |  Germany Italy Poland Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 23 sites across their trial portfolio.
Therapeutic Focus
- 1.Respiratory Tract Diseases1 trial277 other sponsors
Partnered Research Centres
23 centres- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Viale Luigi Pinto 1, 71122 Foggia
- Address
- Via Santa Sofia 78, 95123 Catania
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
- Address
- Dr. Molewaterplein 40, 3015 GD Rotterdam
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Trevi Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.